Improvements in antenatal screening for Down's syndrome

Journal of Medical Screening

Volumn 20, Issue 1, 2013, Pages 7-14

  Wald, N J ^a   Bestwick, J P ^a   Huttly, W J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR;

BLOOD; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LABORATORY DIAGNOSIS; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; SECOND TRIMESTER PREGNANCY; ARTICLE; METHODOLOGY;

DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 84875188034     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141313476496     Document Type: Article

References (17)

1. Borrell A, Borobio V, Bestwick JP, Wald NJ. Ductus venosus pulsatility index as an antenatal screening marker for Down's syndrome: Use with the Combined and Integrated tests. J Med Screen 2009;16:112-118
2. Cicero S, Rembouskos G, Vandecruys H, Hogg M, Nicolaides KH. Likelihood ratio for trisomy 21 in foetuses with absent nasal bone at the 11-14-week scan. Ultrasound Obstet Gynecol 2004;23:218-223
3. Wald NJ, Bestwick JP, Huttly WJ. Antenatal screening for Down syndrome using serum placental growth factor with the Combined, Quadruple, serum Integrated and Integrated tests. PloS ONE 2012;7:e46955
4. Bestwick JP, Huttly WJ, Wald NJ. Distribution of nuchal translucency in antenatal screening for Down's syndrome. J Med Screen 2010;17:8-12
5. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104
6. Wald NJ, Rodeck C, Hackshaw AK, et al. Correction to SURUSS report. J Med Screen 2006;13:51-52
7. Wald N, Rodeck C, Rudnicka A, Hackshaw A. Nuchal translucency and gestational age. Prenat Diagn 2004;24:150-151
8. Office for National Statistics. Birth statistics. England and Wales; 2006, 2007, 2008 (FM1, Nos 35-37). London: The Stationary Office, 2008
9. Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2-6
10. Morris JK, Wald NJ, Mutton DE, Alberman E. Comparisons of models of maternal age-specific risk for Down syndrome live births. Prenat Diagn 2003;23:252-258
11. Morris J, Mutton D, Alberman E. Corrections to maternal age-specific live birth prevalence of Down's syndrome. J Med Screen 2005;12:202
12. Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-145
13. Kanellopoulos V, Katsetos C, Economides DL. Examination of fetal nasal bone and repeatability of measurement in early pregnancy. Ultrasound Obstet Gynecol 2003;22:131-134
14. Borrell A, Martinez JM, Serés A, Borobio V, Cararach V, Fortung A. Ductus venosus assessment at the time of nuchal translucency measurement in the detection of fetal aneuploidy. Prenat Diagn 2003;23:921-926
15. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-1002
16. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal Blood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901
17. Sparks AB, Stuble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1-9